The purpose of the iNNOVATE study (NCT02165397) was to evaluate the safety and efficacy of ibrutinib and rituximab for the treatment of Waldenströms macroglobulinemia (WM). Here, at the 23rd congress of the European Haematology Association (EHA) 2018, held in Stockholm, Sweden, Meletios Dimopoulos, MD, from Kapodistrian University of Athens School of Medicine, Athens, Greece, discusses the results of this Phase III trial. Dr Dimopoulos highlights how this trial has produced exciting results in terms of patient outcomes; surprisingly, most of all in high risk patient groups. Improvements for the future are then discussed, looking at treatment duration and other drug combinations.
iNNOVATE results: a prospective new standard of care for Waldenström’s macroglobulinemia
